Replies to post #179651 on Biotech Values

[DewDiligence]

Coherus starts phase-3 trial of Enbrel FoB (for non-US markets):

http://finance.yahoo.com/news/coherus-announces-initiation-phase-3-162100175.html

Coherus is collobarating with BAX to commercialize an Enbrel FoB in the EU, Canada, and Brazil (#msg-91645674) and is collaborating with Daiichi Sankyo in Japan, South Korea, and Taiwan (#msg-75397629). The US market is not being pursued because of AMGN’s long-running patent protection (#msg-69263618).

[DewDiligence]

Liomont, Oncobiologics ink FoB collaboration for commercialization in Mexico:

http://finance.yahoo.com/news/liomont-oncobiologics-partner-launch-biosimilars-133000786.html

Oncobiologics, Inc. and Laboratorios Liomont S.A. de C.V. announced today a strategic partnership for the development, manufacture and commercialization of biosimilar monoclonal antibody products for the Mexican market. The scope of the agreement includes exclusive commercialization in Mexico by Liomont of two biosimilars developed by Oncobiologics.

Under the agreement, Liomont, a leading Mexico City-based pharmaceutical company, will provide Oncobiologics with upfront licensing and development milestone payments, as well as royalties once the medicines are commercialized. Oncobiologics will oversee global clinical trials and will provide commercial supply manufacturing for launch in the Mexican market.

Both companies are private; financial terms were not disclosed.

[DewDiligence]

Announced FoB Collaborations

[Added entry for Liomont-Oncobiologics.]


Items are shown in reverse chronological order. This table does not purport to be exhaustive.

 
                     Date   Targets   Geography     iHub References 
 Liomont-Oncobiolgcs 6/14   2 mAbs    Maxico        #msg-103754486 
 PlantForm-PhrmaPrxs 6/14   Avastin+  Brazil        #msg-103576633 
 Lupin-Yoshindo      4/14   Enbrel+   Japan         #msg-101018361 
 BAX-Coherus         9/13   Enbrel    ex-US         #msg-91645674 
 Oncobiolgcs-Huahai  5/13   #         global        #msg-87734336,#msg-87744882 
 Strides-Pfenex      4/13   Betaseron global        #msg-87014470 
 MRK-Samsng/BIIB     2/13   @         Europe+       #msg-84781042,#msg-69629103,#msg-95065880 
 Catalent-UMN       12/12   various   Asia          #msg-82556713 
 Merck KGaA-RDY      6/12   oncology  global        #msg-76359649 
 Daiichi-Coherus     5/12   *         Asia          #msg-75397629 
 Fujifilm-Kyowa      3/12   Humira    unspecified   #msg-73800486 
 ACT-Bioton          2/12   insulin   US & Europe   #msg-74987123 
 ACT-AMGN           12/11   †         global        #msg-70097496,#msg-84340328 
 BAX-MNTA           12/11   ‡         global        #msg-70212854,#msg-70258421 
 HSP-Celltrion      10/09   z         global        #msg-84519981,#msg-77816122 
 MYL-Biocon          6/09   x         global        #msg-72421544,#msg-84561737 
 Procognia-UTR       n/a    Humira    unspecified   #msg-84340976 

*Enbrel and Rituxan.

†Humira, Remicade, Herceptin, Avastin, Rituxan, Erbitux; excludes AMGN FoB’s for AMGN’s branded drugs.

‡Three products in development: 2 auto-immune and 1 oncology—my guesses are Humira, Orenica, Erbitux; may include up to 6 products eventually.

@ Samsung/BIIB subordinate collaboration known as Samsung Bioepis developing Remicade and Enbrel FoB’s in Europe (#msg-95065880); Rituxan program terminated (#msg-80622249).

#Humira, Rituxan, Avastin, Herceptin.

x Nine products: Herceptin, Neulasta, Avastin, Humira, Enbrel, Lantus, Novolog, Humalog, one undisclosed.

y Rituxan program terminated (#msg-80236315); status of other programs unknown.

z Each company received a distinct EU/CHMP approval for Remicade on 6/28/13; partnership includes seven (other) products: Rituxan, Herceptin, Enbrel, Erbitux, Synagis, Humira, Avastin.